CurrentCignaPolicy IP0534

Abilify Mycite (aripiprazole tablets with Ingestible Event Marker) Coverage Policy

Defines Cigna's coverage position for Abilify Mycite (aripiprazole with an ingestible event marker) for adults with schizophrenia, bipolar I disorder, and adjunctive treatment for major depressive disorder; applies to Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyAbilify Mycite (aripiprazole tablets with Ingestible Event Marker)

Policy CodePolicy IP0534

Change TypeNo material change

Effective DateFeb 1, 2023

Next Review DateFeb 1, 2024

Key ActionConfirm coverage depends on the applicable benefit plan's medical necessity definition and prefer the most cost-effective equivalent (generic aripiprazole) before Mycite when plan limits apply.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3FDA-approved indications listed

Not superiorNot shown superior to generic

Limitations notedCompliance/real-time tracking

IP0534Policy ID

Coverage Criteria for Abilify Mycite

Policy Summary

PayerCigna

PolicyAbilify Mycite (aripiprazole tablets with Ingestible Event Marker)

Policy CodePolicy IP0534

Change TypeNo material change

Effective DateFeb 1, 2023

Next Review DateFeb 1, 2024

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage limitation based on cost-effectiveness

Not considered medically necessary when the plan limits coverage to the most cost-effective equivalent treatment

Not medically necessary when cost-effective equivalent required: The effectiveness of Abilify Mycite has not been demonstrated as clinically superior to generic aripiprazole and is significantly more expensive; where the plan's medical necessity definition limits coverage to the most cost‑effective equivalent treatment, Abilify Mycite is not considered medically necessary.

Supports denial based on cost-effectiveness

Abilify Mycite (aripiprazole tablets with an Ingestible Event Marker sensor) is not considered medically necessary when the applicable health benefit plan’s medical necessity definition limits coverage to the most cost‑effective equivalent treatment.

Rationale: the policy states the effectiveness of Abilify Mycite has not been demonstrated as clinically superior to generic aripiprazole for FDA‑approved indications and it is significantly more expensive; therefore, where a plan requires the most cost‑effective equivalent treatment, Abilify Mycite is not considered medically necessary and may be denied.

Provider Action and Determination Guidance

Prior Authorization

Medical necessity / cost-effectiveness requirement

Coverage of Abilify Mycite (aripiprazole tablets with an Ingestible Event Marker sensor) depends on the terms of the applicable benefit plan document. If a member's plan definition of medical necessity or coverage limits treatment to the most cost-effective equivalent, coverage is restricted to generic aripiprazole and Abilify Mycite is not considered medically necessary.

Affected drug: Abilify Mycite (aripiprazole with IEM sensor)
Preferred alternative: Generic aripiprazole
Effective Date: 2023-02-01
Policy Number: IP0534

Documentation Required

Determination considerations

When making a determination, reviewers must consider: 1) the specific terms of the member's benefit plan document in effect on the date of service (Group Service Agreement, Evidence of Coverage, Certificate of Coverage, SPD, or similar); 2) any applicable federal or state laws and regulations; 3) relevant clinical evidence and Coverage Policies; and 4) the individual clinical facts presented for the member.

Verify plan language for medical necessity and cost-effectiveness provisions
Document clinical rationale if requesting coverage of Abilify Mycite over generic aripiprazole
Confirm date of service falls within the plan period referenced

Step Therapy

Step or cost-preference implication

Step-therapy / cost-preference implication: Plans that limit covered treatment to the most cost-effective equivalent will require use of generic aripiprazole prior to approval of Abilify Mycite. Failure to follow such step or preference requirements may result in denial of coverage for Abilify Mycite.

Preferred agent: generic aripiprazole (use before Abilify Mycite when plan requires most cost-effective equivalent)
Denial risk: Requests for Abilify Mycite may be denied if plan enforces cost-preference or step-therapy to cheaper equivalents

Denial Risk

Cost-effectiveness denial risk

Denial risk: Because Abilify Mycite is more costly and lacks demonstrated clinical superiority to generic aripiprazole for indicated adult conditions, it is not considered medically necessary and may be denied when the applicable benefit plan limits coverage to the most cost-effective equivalent.

Abilify Mycite may be denied as not medically necessary when plan language restricts coverage to cost-effective equivalents
Provide detailed clinical justification and evidence if requesting exception

Background

Background: Abilify Mycite is a drug‑device combination consisting of aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor intended to track ingestion. The policy notes that its effectiveness has not been shown superior to generic aripiprazole and that plan coverage may be limited when the plan definition of medical necessity requires the most cost‑effective equivalent treatment.

Definitions

inv-09: Abilify Mycite — key properties, FDA approvals and indications

ProductAbilify Mycite (aripiprazole tablets with Ingestible Event Marker sensor)

FDA‑approved indicationsTreatment of adults with schizophrenia; treatment of bipolar I disorder (acute and maintenance; as monotherapy and adjunct to lithium or valproate); adjunctive treatment of adults with major depressive disorder (MDD)

Product typeDrug‑device combination product (aripiprazole tablets embedded with an Ingestible Event Marker sensor)

Intended function of IEM sensorTracks drug ingestion (ingestible event marker to detect ingestion)

Notes on policy coverage contextPolicy addresses use of aripiprazole with IEM sensor and cites FDA approvals for adult schizophrenia, bipolar I disorder, and adjunctive MDD treatment.

Initial Therapy Limitations

Limitations of Use

Limitations: The ability of Abilify Mycite to improve patient compliance or modify aripiprazole dosage has not been established; use to track drug ingestion in real-time or during an emergency is not recommended because detection may be delayed or may not occur.

Clinical performance limitations of the IEM sensor

Step Therapy / Cost-Preference

Step	Preferred therapy	Non-preferred therapy	Coverage implication
1	Generic aripiprazole	Abilify Mycite (aripiprazole with IEM sensor)	Abilify Mycite is not considered medically necessary where the applicable health benefit plan limits coverage to the most cost‑effective equivalent treatment because it has not been shown clinically superior to generic aripiprazole and is significantly more expensive.